New study aims to unlock why some children with hemophilia reject treatment

NCT ID NCT07539402

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will follow 500 children with hemophilia A who use non-factor therapy to prevent bleeding. Researchers want to understand why some children develop antibodies against factor VIII while others do not. By studying blood and stool samples over time, they hope to uncover the immune mechanisms behind tolerance. The study does not test a new treatment but aims to inform future therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how the immune system learns to accept factor VIII, potentially guiding better treatments for hemophilia A.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test a new therapy, and results may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam UMC, locatie AMC

    Amsterdam, North Holland, 1105AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.